Valor202020212022202320242025TTMFluxo de caixa de investimento-730 K-9.84 M6.73 M-1.32 M-2.41 M-801 K-754 KFluxo de caixa de financiamento2.37 M83.01 M207 K22.7 M-6.81 M35.85 M11.3 MFluxo de caixa livre-29.12 M-30.34 M-34.01 M-34.41 M-32.46 M-21.18 M-13.58 M
Neuronetics, Inc. - Common Stock
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
Neuronetics became the "first and only Food and Drug Administration approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device."
They manufacture a transcranial magnetic stimulation device, NeuroStar. The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.